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Results: The percentage of pls pfescnb?cJ CCBs. rr bkxkers drurehcs. 
and ACE-i). as mono-or combinabon tfrerapy by year IS shown at right 
CCB use among hypertensms tih fir51 AM1 mcreased drmat~calty (p . 
O.OOl) dunng the stu@y period. such that CCBs were lhe most commonfy 
prescribed agenl after 1993. The advent 01 CC&and ACE-I comcrded v&r an 
overall decrease m fi Mocker and druretrc use. though from 1993-5. foltowrrrg 
pubkcatron of JNC V. thus trend reversed CCEf use appeared unaffected by 
JNC V ncommendatcns. 
ConcIusM: These populahon-hased lmdtngs suggest marked changes 
in practice patterns in hypertensives at nsk for AMI. 
I_-3 1026 68 Active Control Trlats: What About a Placebo? A 
Method lllustratad With Clopldogral. Aspirin and 
Placebo 
L.D. Fisher. Umwrsify of Washrngton Sean/e. WA. USA 
&c@roundr Cardiovascular drug approval IS mcreasmgly dependent on 
active conlml trials for elhical reasons. For regulatory approval it IS necessary 
to rllustrate that a drug would have beaten placebo. Supportwe analyses to 
an active conlml trial(s) are needed in order to estimate what might Cave 
happened it there had been a placebo treatment arm. 
Methods: A new method combmes an active control trial with a number of 
separate placebo contmlled trials against the aclive comparator. The method 
uses the logarithm 01 the odds ratio for the first occurrence of an event and 
estimates: i) the odds ratio for the new dNg versus placebo and ii) a 95% 
confidence interval for the estimate. 
///usriarion: The CAPRIE trial of 75 mg of Clopidogrel versus 325 mg 
of Aspirin studied more lhan 19.000 patients with recent prior ischemic 
Stroke, myWardiaf infamlion or penpheraf edeiiaf ZWaSe. (Lancet. 1996: 
349: 1329-39). Aspirin versus placebo was evaluated in a meta-analysis: 
Anttpfalefel Tnalmr Coflahoralron (W&I. 1994 308 91-108) These TV 
SouKW are used to IllustfalQ the method wtth four ondpomtl, I) thn &dl?f 
01 aft strokes. MI of va~uhr deam: II) 8q m I) pf~ dean from any c~usfj 
III) vsscutar death and IV) cMath tram any cause. ti m~thcd and grap&c 
presentalm of lhe rQrutt8 arQ @WI. estlmatinq m hlehty ataltrfkxffy e 
ncflcant CWdogrel v~mus) placabd resuL (p =’ 00001 for Ike ctuaitsr 0t 
events). Tha 5~~3nl1f1c Cogancy, etrsntxhs and weaknees~a of such anam 
are &sc~sed. 
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In cofrdu5100. a large eomofmc beMm wnh0ut dfwxeaf.0 m quality of 
care was noted wtm the use of POCT for management of hepann therapy 
fofklwlng coronary mterverltron 
1026-70 Calcium Charm4 Mockam and Canecr. No 
Evldance of an Increased Risk. 
Samuel Shaprm. Lynn Rosenberg. Bosfon Utnvwmry. lbfon. MA. USA 
83ck9mtmct The qmkrmotcg~~ studtes have suggested that cafckrm &an- 
nel bfocken (CCBs) trmease the risk d several cancers. One study has 
SuggesM lhat CC& may cause breast cancer, and mteract wtth estrogen 
supplements. 
Mefhats In a large ~fmfStL@OfrWlyCZWPXrSconductedhmng 
lse3-199sa~patrents40to69yeandapinhoJpitafJmBslhmns. 
New York and Phtladelphra 9513 cancer cases were compared wlfr 6492 
COlllrdS. 
f+sum; The use of CCEts (mean duratron 3.8 years) was noI -ated 
wrn cancer overall (relattve risk. 1 .l %: 95% conl~r!ence m?erval O.!+-1.3). Nor 
were CCBs assocrafed wttfr mdwrdual cancers, mcfuding ffmse prewously 
rmplrcated. wrM the exceptron of renal cancer. Agam with ffm exception of 
renal cancer. beta-blockers and a~otensmccmterfmg enzyme mhlbrtors 
were also unrelated to cancer mk. Renal cancer has been assoctaled wrth 
hypertensron (and druqs used to treat hypeltennon) m preWou!3 SWdleS. 
Among 2993 cases of breast cancer the relative mk for CCB usa was 1.1 
(95% confidence Interval 0.9-r .4) and there was no evrdence of mteractlcm 
wrth estrogen supplements. 
Conc/usrons: The ftndmgs suggest lhat CC& do not cause cancer 
